Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021.
Ann Hepatol
; 29(4): 101509, 2024.
Article
em En
| MEDLINE
| ID: mdl-38710472
ABSTRACT
INTRODUCTION AND OBJECTIVES:
Treatment of chronic hepatitis B (CHB) with nucelos(t)ide analogues (NA) can improve outcomes, but NA treatment is expensive for insurance plans. MATERIALS ANDMETHODS:
The Centers for Medicare & Medicaid Services database was assessed from 2012 to 2021 to assess the use of NA for CHB in patients on Medicaid. Data extracted included the number of claims, units, and costs of each agent stratified by originator and generic.RESULTS:
Over the study period, 1.9 billion USD was spent on NA, with spending peaking in 2016 at $289 million US, which has subsequently decreased. Lower expenditures since 2016 have been associated with increased use of generics. The use of generic tenofovir or entecavir led to savings of $669 million US over the study period.CONCLUSIONS:
Increased generic use has significantly reduced expenditures for NA drugs; policy shifts towards generic drug use may help with sustainability.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Medicaid
/
Medicamentos Genéricos
/
Custos de Medicamentos
/
Gastos em Saúde
/
Hepatite B Crônica
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Ann Hepatol
Assunto da revista:
GASTROENTEROLOGIA
Ano de publicação:
2024
Tipo de documento:
Article